Gritstone Bio PE Ratio 2017-2022 | GRTS

Current and historical p/e ratio for Gritstone Bio (GRTS) from 2017 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Gritstone Bio PE ratio as of May 24, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Gritstone Bio PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-25 1.77 0.00
2022-03-31 4.12 $-1.05 0.00
2021-12-31 12.86 $-0.95 0.00
2021-09-30 10.80 $-1.28 0.00
2021-06-30 9.13 $-1.61 0.00
2021-03-31 9.43 $-1.97 0.00
2020-12-31 3.94 $-2.78 0.00
2020-09-30 2.65 $-2.86 0.00
2020-06-30 6.64 $-2.94 0.00
2020-03-31 5.82 $-2.88 0.00
2019-12-31 8.97 $-2.79 0.00
2019-09-30 8.64 $-2.63 0.00
2019-06-30 11.14 $-9.46 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.131B $0.048B
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00